Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience

<div>Pathological complete response rate by hormone receptor status. (a) Overall pCR rate (ypT0/is, N0) rate (b) pCR rate based on ER and PgR status of tumours where available. ER: estrogen receptor; PgR: progesterone receptor.</div>

The Breast Journal

fig1

Figure 1

Figure 1: Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience 